Literature DB >> 24195019

Potential for misdiagnosis in community-acquired PET scans for dementia.

Sheena M Shipley1, Meredith C Frederick, Christopher M Filley, Benzi M Kluger.   

Abstract

We reviewed records of patients seen in a tertiary Neurobehavior Clinic to identify those who had community-acquired PET scans as part of their dementia diagnostic evaluation with the goal of assessing factors influencing diagnostic accuracy. We compared outside radiologist PET diagnoses to our consensus clinical diagnosis and collected data regarding clinical variables, ordering reasons, and specialties of interpreting and ordering physicians. Among 1,580 total patients seen in our clinic, 46 met our inclusion criteria. There was disagreement between outside diagnosis based on PET and our consensus diagnosis in 65% (n = 30) of patients. Community-acquired PET scans may have lower diagnostic value in dementia evaluation than suggested by prior research and may be associated with significant risks including misdiagnosis with an incurable neurodegenerative disease.

Entities:  

Year:  2013        PMID: 24195019      PMCID: PMC3787114          DOI: 10.1212/CPJ.0b013e318296f2df

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  14 in total

1.  Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

Authors:  K Herholz; E Salmon; D Perani; J C Baron; V Holthoff; L Frölich; P Schönknecht; K Ito; R Mielke; E Kalbe; G Zündorf; X Delbeuck; O Pelati; D Anchisi; F Fazio; N Kerrouche; B Desgranges; F Eustache; B Beuthien-Baumann; C Menzel; J Schröder; T Kato; Y Arahata; M Henze; W D Heiss
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

2.  Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.

Authors:  Michael Schöll; Anders Wall; Steinunn Thordardottir; Daniel Ferreira; Nenad Bogdanovic; Bengt Långström; Ove Almkvist; Caroline Graff; Agneta Nordberg
Journal:  Neurology       Date:  2012-06-13       Impact factor: 9.910

3.  Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  D S Knopman; S T DeKosky; J L Cummings; H Chui; J Corey-Bloom; N Relkin; G W Small; B Miller; J C Stevens
Journal:  Neurology       Date:  2001-05-08       Impact factor: 9.910

Review 4.  Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature.

Authors:  Nicolaas I Bohnen; David S W Djang; Karl Herholz; Yoshimi Anzai; Satoshi Minoshima
Journal:  J Nucl Med       Date:  2011-12-15       Impact factor: 10.057

5.  Validating FDG-PET as a biomarker for frontotemporal dementia.

Authors:  Norman L Foster
Journal:  Exp Neurol       Date:  2003-11       Impact factor: 5.330

Review 6.  The morbid anatomy of dementia in Parkinson's disease.

Authors:  Michail E Kalaitzakis; Ronald K B Pearce
Journal:  Acta Neuropathol       Date:  2009-10-10       Impact factor: 17.088

7.  Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease.

Authors:  P V Arriagada; K Marzloff; B T Hyman
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

8.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

Review 9.  Alzheimer disease: operating characteristics of PET--a meta-analysis.

Authors:  Meenal B Patwardhan; Douglas C McCrory; David B Matchar; Gregory P Samsa; Olivier T Rutschmann
Journal:  Radiology       Date:  2004-02-27       Impact factor: 11.105

10.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.

Authors:  S Minoshima; K A Frey; R A Koeppe; N L Foster; D E Kuhl
Journal:  J Nucl Med       Date:  1995-07       Impact factor: 10.057

View more
  4 in total

1.  Using redescription mining to relate clinical and biological characteristics of cognitively impaired and Alzheimer's disease patients.

Authors:  Matej Mihelčić; Goran Šimić; Mirjana Babić Leko; Nada Lavrač; Sašo Džeroski; Tomislav Šmuc
Journal:  PLoS One       Date:  2017-10-31       Impact factor: 3.240

Review 2.  An Algorithm for Preclinical Diagnosis of Alzheimer's Disease.

Authors:  Tapan K Khan
Journal:  Front Neurosci       Date:  2018-04-30       Impact factor: 4.677

3.  High-throughput epitope profiling of antibodies in the plasma of Alzheimer's disease patients using random peptide microarrays.

Authors:  Kyu-Young Sim; Sang-Heon Park; Kyu Yeong Choi; Jung Eun Park; Jung Sup Lee; Byeong C Kim; Jeonghwan Gwak; Woo Keun Song; Kun Ho Lee; Sung-Gyoo Park
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

Review 4.  Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?

Authors:  Emilio Merlo Pich; Andreas Jeromin; Giovanni B Frisoni; Derek Hill; Andrew Lockhart; Mark E Schmidt; Martin R Turner; Stefania Mondello; William Z Potter
Journal:  Alzheimers Res Ther       Date:  2014-07-30       Impact factor: 6.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.